Immunovant, Inc. Stock News

Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech com

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, cou

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Tuesday, Immunovant announced early-stage trial results for an autoimmune disease candidate that caused its shares to rocket higher. Investors are bidding up the stock again today, presumably due to i

Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confidence, and we expect more upside from here. IMVT-1402

Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.

Immunovant reported positive phase 1 trial data for IMVT-1402. The company said the therapy showed a strong safety profile and fewer side effects than batoclimab.

There was a bumper boost for stock in two Nasdaq-listed biotechs premarket after an experimental antibody treatment was revealed to have blockbuster potential. Shares of Immunovant surged 59% after th

Markets moved lower on Tuesday, giving up some gains from Monday. Immunovant released positive trial data that sent its shares soaring.